|
Issues covered will
include:
·
How should risk be viewed by governance?
·
What relationships should exist between stage gates’ review
boards and governance bodies?
·
Finance versus Science - where does the balance lie?
·
Do current pharma and biotech
organizational structures support effective governance?
·
How effective is the decision making process?
·
What do governance bodies require to make effective decisions?
·
Project review board or governance body?
|